SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Howard Hoffman who wrote (1051)6/25/1997 1:53:00 AM
From: Pseudo Biologist   of 1762
 
Howard, I am sure Brad, Bennett and others can do better, but in the meantime here is my attempt: very low CD4 counts mean serious immunosupression. For example, AIDS patients have their CD4+ cell count carefully monitored, and this number is often used as a main indicator of how well or poorly the patients are doing.

RA and other autoimmune conditions are the reverse in some sense: the body's defenses are "too active" and start attacking parts of itself (e.g joints). Anti-RA strategies walk a fine line of creating selective or moderate immunosupression: you do not want to go too far and give people "artificial" AIDS (I do not think CE9 is ANYWHERE CLOSE from doing this, but you have to be very conservative with new drugs). Some anti-CD4 Mabs are depleting (destroy) of CD4+ cells. It was believed that CE9.1 was not(too) depleting. It is hard to tell if this is "it" for CE9; if the second generation drug works better, then CE9 is dead (but not IDEC).

I understand that J & J as well as Glaxo are developing humanized anti-CD4 Abs for RA (huOKT4A and 4162W94, respectively). These are in phase I/II or II. How these do may give a clue on whether *any* anti-CD4 MAb therapy has any chance of working in this context.

Hope this helps,

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News